ClinicalTrials.Veeva

Menu

Study on Antigen-presenting Function of Gamma Delta T Cells in Sepsis and Its Molecular Mechanisms

S

Sichuan University

Status

Unknown

Conditions

γδ T Cells
Sepsis
Antigen-presenting Function

Treatments

Other: Collect peripheral blood sample

Study type

Observational

Funder types

Other

Identifiers

NCT03379896
81701880

Details and patient eligibility

About

Study on antigen-presenting function of gamma delta T cells in sepsis and its molecular mechanisms

Full description

The latest definition of sepsis highlights the role of dysregulated host response to infection in organ dysfunction aggravation. Maintenance of immune homeostasis of septic patients through immunotherapy is the key breakthrough to improve success rate. Antigen-presenting cell (APC) is the bridge that connects the innate and adaptive immunity. Decrease of count and function of APC has been shown to be associated with worsened clinical outcomes in patients with sepsis. Gamma-delta T cells (γδ T cells) are the newly identified population of T lymphocytes. Recent studies have found that γδ T cells possess unique and powerful antigen-presenting function, making them the hot topic in infection and cancer research. Based on the results, the investigator plan to evaluate the antigen-presenting function changes of γδ T cells in septic status by analyzing the antigen-presenting related molecules on γδ T cells, antigen protein uptake ability, and their function on the proliferation and activation of CD8+ T lymphocytes. Furthermore, the investigator will explore the mechanism and signal pathways for the APC function changes of γδ T cells. Findings from this research could help explain the mechanism of sepsis induced immune dysfunction, enrich our understanding of the important role of γδ T cells, and build a good foundation for immunotherapy in sepsis.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. ≥18 year old;
  2. a known or suspected infection based on clinical data at the time of admission and sepsis-induced dysfunction of at least one organ.

Exclusion criteria

  1. autoimmune disease,
  2. history of transplantation,
  3. acute tuberculosis,
  4. chronic hepatitis B or C infection,
  5. HIV infection,
  6. active malignancy, and
  7. long-term use of cortical steroids.

Trial design

60 participants in 2 patient groups

Sepsis
Description:
Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
Treatment:
Other: Collect peripheral blood sample
Control
Description:
Age-matched healthy control
Treatment:
Other: Collect peripheral blood sample

Trial contacts and locations

0

Loading...

Central trial contact

Xuelian Liao, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems